From MarketBeat:

Pulmonx Co. insider, Geoffrey Beran Rose, sold 1,184 shares of the company’s stock at an average price of $12.75, bringing in a total of $15,096. This follows a previous sale of 2,868 shares on December 1st and 1,184 shares on November 22nd. Pulmonx stock trading currently sits at $13.07 and their quarterly earnings beat market expectations.

Institutional investors in the company include Point72 Hong Kong Ltd, Ensign Peak Advisors Inc, and State of Wyoming, among others. Wall Street analysts have commented on Pulmonx, with Canaccord Genuity Group lowering their price objective to $12.00 and setting a “buy” rating, while Craig Hallum and Piper Sandler both gave a “buy” recommendation.

Pulmonx, a company specializing in minimally invasive devices for chronic obstructive pulmonary diseases, has seen a recent surge in stock trading and analyst predictions. Pulmonx is involved in the treatment of patients with severe emphysema and has shown positive revenue growth. 88.09% of the company’s stock is owned by institutional investors and hedge funds.



Read more: Pulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 1,184 Shares